Insider trade

Eli Lilly (LLY): Director received 4.39 shares

Gabrielle Sulzberger, Director at Eli Lilly, reported a grant / award of 4.39 shares.

4.39
Shares · @ $1,129.35
Traded
Jun 15, 2026
Filed
Jun 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 2, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  2. Jan 2, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  3. Mar 27, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  4. Apr 2, 2026Congress · 1 personMembers of Congress: 2 purchases
  5. Apr 8, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  6. Apr 14, 2026CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
  7. Apr 20, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.7%
  8. Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
  9. May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 6.5%
  10. May 6, 2026Insider · 1 personInsiders: 2 sales (~$15.8M)
  11. May 15, 2026Federal contract · $52K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $52K obligated to date
  12. Jun 9, 2026FDAFDA drug approval: Ebglyss
  13. Jun 10, 2026Insider · Their largest sale since 2022Officer sold ~$2.88M of LLY shares in the open market
  14. Jun 10, 2026Congress · 1 personMembers of Congress: 2 purchases

What came next

  1. Jul 1, 2026CongressDisclosed sale of LLY — reported range $1,001 - $15,000
  2. Jul 10, 2026CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
  3. Jul 13, 2026FDAFDA drug approval: Verzenio
  4. Jul 14, 2026FDAFDA drug approval: Retevmo
  5. Jul 14, 2026FDAFDA drug approval: Retevmo
  6. Jul 23, 20265% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 9.6%
  7. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
  8. Aug 7, 2026InsiderOfficer sold ~$5.95M of LLY shares in the open market
  9. Aug 10, 2026Insider · Their largest sale since 2014Officer sold ~$2.37M of LLY shares in the open market
  10. Aug 17, 2026Federal contract · $5K obligatedDepartment of Veterans Affairs awarded Eli Lilly: $4.5K obligated to date
  11. Aug 17, 2026Insider · Their largest sale since 2022Officer sold ~$7.64M of LLY shares in the open market
  12. Aug 26, 2026FDAFDA drug approval: Zepbound
  13. Aug 27, 2026FDAFDA drug approval: Mounjaro
  14. Aug 27, 2026FDAFDA drug approval: Mounjaro
  15. Sep 18, 2026FDAFDA drug approval: Inluriyo
  16. Sep 18, 2026FDAFDA drug approval: Verzenio
  17. Sep 23, 2026FDAFDA drug approval: Onswik
  18. Sep 25, 2026FDAFDA drug approval: Olumiant
  19. Oct 9, 2026FDAFDA drug approval: Olumiant
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by Gabrielle Sulzberger, Director

The full history of Gabrielle Sulzberger, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Eli Lilly (LLY) insider traded, and how much?

Gabrielle Sulzberger, Director at Eli Lilly, reported a grant / award of 4.39 shares. At $1,129.35.

When did it happen, and when was it made public?

Traded: Jun 15, 2026. Filed: Jun 16, 2026. That is 1 day between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Eli Lilly recently?

For Eli Lilly, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 5 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days. They are listed on the LLY page.

Does this mean LLY stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Eli Lilly

Everything OQRO holds on this company is on its LLY page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data